Literature DB >> 16832357

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.

Anthony Renwick1, Deborah Thompson, Sheila Seal, Patrick Kelly, Tasnim Chagtai, Munaza Ahmed, Bernard North, Hiran Jayatilake, Rita Barfoot, Katarina Spanova, Lesley McGuffog, D Gareth Evans, Diana Eccles, Douglas F Easton, Michael R Stratton, Nazneen Rahman.   

Abstract

We screened individuals from 443 familial breast cancer pedigrees and 521 controls for ATM sequence variants and identified 12 mutations in affected individuals and two in controls (P = 0.0047). The results demonstrate that ATM mutations that cause ataxia-telangiectasia in biallelic carriers are breast cancer susceptibility alleles in monoallelic carriers, with an estimated relative risk of 2.37 (95% confidence interval (c.i.) = 1.51-3.78, P = 0.0003). There was no evidence that other classes of ATM variant confer a risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16832357     DOI: 10.1038/ng1837

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  267 in total

Review 1.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.

Authors:  Ben Zhang; Alicia Beeghly-Fadiel; Jirong Long; Wei Zheng
Journal:  Lancet Oncol       Date:  2011-04-20       Impact factor: 41.316

2.  Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients.

Authors:  Jana Soukupova; Petr Pohlreich; Eva Seemanova
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

Review 3.  An updated review of epidemiology, risk factors, and management of male breast cancer.

Authors:  Noman Ahmed Jang Khan; Maria Tirona
Journal:  Med Oncol       Date:  2021-03-15       Impact factor: 3.064

4.  Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells.

Authors:  Stefano J Mandriota; Raphaële Buser; Laurence Lesne; Christelle Stouder; Vincent Favaudon; Pierre Maechler; Frédérique Béna; Virginie Clément; Curzio Rüegg; Roberto Montesano; André-Pascal Sappino
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

5.  Tests of association for rare variants: case control mutation screening.

Authors:  Sean V Tavtigian; Mia Hashibe; Alun Thomas
Journal:  Nat Rev Genet       Date:  2011-02-01       Impact factor: 53.242

Review 6.  The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition.

Authors:  Anosheh Afghahi; Allison W Kurian
Journal:  Curr Treat Options Oncol       Date:  2017-05

7.  Rho GTPase independent regulation of ATM activation and cell survival by the RhoGEF Net1A.

Authors:  Wonkyung Oh; Jeffrey A Frost
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.

Authors:  G Cecener; G Guney Eskiler; U Egeli; B Tunca; A Alemdar; S Gokgoz; I Tasdelen
Journal:  Mol Biol Rep       Date:  2016-08-29       Impact factor: 2.316

9.  Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.

Authors:  Sean V Tavtigian; Graham B Byrnes; David E Goldgar; Alun Thomas
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

10.  p53 centrosomal localization diagnoses ataxia-telangiectasia homozygotes and heterozygotes.

Authors:  Andrea Prodosmo; Andrea De Amicis; Cecilia Nisticò; Mario Gabriele; Giuliana Di Rocco; Laura Monteonofrio; Maria Piane; Enrico Cundari; Luciana Chessa; Silvia Soddu
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.